Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

Abstract Introduction Sotrovimab, a recombinant human monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had US Food and Drug Administration Emergency Use Authorization for the treatment of high-risk outpatients with mild-to-moderate coronavirus disease 20...

Full description

Bibliographic Details
Main Authors: Mindy M. Cheng, Carolina Reyes, Sacha Satram, Helen Birch, Daniel C. Gibbons, Myriam Drysdale, Christopher F. Bell, Anvar Suyundikov, Xiao Ding, M. Cyrus Maher, Wendy Yeh, Amalio Telenti, Lawrence Corey
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-01-01
Series:Infectious Diseases and Therapy
Subjects:
COVID-19
Effectiveness
Monoclonal antibody
SARS-CoV-2
Sotrovimab
Real-world
Online Access:https://doi.org/10.1007/s40121-022-00755-0

Internet

https://doi.org/10.1007/s40121-022-00755-0

Similar Items